Treating head and neck cancer in the age of immunotherapy: a 2023 update
A Bhatia, B Burtness - Drugs, 2023 - Springer
Most patients diagnosed with head and neck squamous cell carcinoma (HNSCC) will
present with locally advanced disease, requiring multimodality therapy. While this approach …
present with locally advanced disease, requiring multimodality therapy. While this approach …
Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments
Head and neck squamous cell carcinoma (HNSCC) comprises a heterogeneous group of
tumors that arise from the squamous epithelium of the oral cavity, oropharynx, larynx and …
tumors that arise from the squamous epithelium of the oral cavity, oropharynx, larynx and …
Pan-cancer computational histopathology reveals mutations, tumor composition and prognosis
We use deep transfer learning to quantify histopathological patterns across 17,355
hematoxylin and eosin-stained histopathology slide images from 28 cancer types and …
hematoxylin and eosin-stained histopathology slide images from 28 cancer types and …
An immune-related gene prognostic index for head and neck squamous cell carcinoma
Y Chen, ZY Li, GQ Zhou, Y Sun - Clinical Cancer Research, 2021 - AACR
Purpose: To construct an immune-related gene prognostic index (IRGPI) for head and neck
squamous cell carcinoma (HNSCC) and clarify the molecular and immune characteristics …
squamous cell carcinoma (HNSCC) and clarify the molecular and immune characteristics …
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
JY Douillard, KS Oliner, S Siena… - … England Journal of …, 2013 - Mass Medical Soc
Background Patients with metastatic colorectal cancer that harbors KRAS mutations in exon
2 do not benefit from anti–epidermal growth factor receptor (EGFR) therapy. Other activating …
2 do not benefit from anti–epidermal growth factor receptor (EGFR) therapy. Other activating …
Tumor mutation burden as a biomarker in resected non–small-cell lung cancer
Purpose The survival benefit with adjuvant chemotherapy for patients with resected stage II-
III non–small-cell lung cancer (NSCLC) is modest. Efforts to develop prognostic or predictive …
III non–small-cell lung cancer (NSCLC) is modest. Efforts to develop prognostic or predictive …
The molecular biology of head and neck cancer
CR Leemans, BJM Braakhuis, RH Brakenhoff - Nature reviews cancer, 2011 - nature.com
Head and neck squamous cell carcinomas (HNSCCs) are caused by tobacco and alcohol
consumption and by infection with high-risk types of human papillomavirus (HPV). Tumours …
consumption and by infection with high-risk types of human papillomavirus (HPV). Tumours …
TP53 Mutations in Head and Neck Squamous Cell Carcinoma and Their Impact on Disease Progression and Treatment Response
G Zhou, Z Liu, JN Myers - Journal of cellular biochemistry, 2016 - Wiley Online Library
Recent studies describing the mutational landscape of head and neck squamous cell
carcinoma (HNSCC) on a genomic scale by our group and others, including The Cancer …
carcinoma (HNSCC) on a genomic scale by our group and others, including The Cancer …
Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers
CR Pickering, J Zhang, SY Yoo, L Bengtsson… - Cancer discovery, 2013 - AACR
The survival of patients with oral squamous cell carcinoma (OSCC) has not changed
significantly in several decades, leading clinicians and investigators to search for promising …
significantly in several decades, leading clinicians and investigators to search for promising …
Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors
M Canale, E Petracci, A Delmonte, E Chiadini… - Clinical Cancer …, 2017 - AACR
Purpose: To analyze the impact of TP53 mutations on response to first-line tyrosine kinase
inhibitors (TKI) in patients with EGFR-mutated non–small cell lung cancer (NSCLC) …
inhibitors (TKI) in patients with EGFR-mutated non–small cell lung cancer (NSCLC) …